metricas
covid
Buscar en
Revista Española de Patología
Toda la web
Inicio Revista Española de Patología Efectos del IFNα y del Lymphomyosot sobre el crecimiento del melanoma B16F10 «...
Journal Information
Vol. 39. Issue 1.
Pages 27-34 (January - March 2006)
Share
Share
Download PDF
More article options
Vol. 39. Issue 1.
Pages 27-34 (January - March 2006)
Originales
Efectos del IFNα y del Lymphomyosot sobre el crecimiento del melanoma B16F10 «in vitro» e «in vivo». Tratamiento con IFNα y Lymphomyosot
Effects of IFNα and Lymphomyosot on «vitro» and «in vivo» B16F10 melanoma growth. Treatment with IFNα and Lymphomyosot
Visits
2162
Fernando Pascual Carpe1, Vicente Vicente Ortega1, Matilde Campos Aranda2, M.ª Josefa Yáñez Gascón1, Juana García Reverte3
Facultad de Medicina. Universidad de Murcia
This item has received
Article information
Resumen
Introducción

En el tratamiento del melanoma se están ensayando distintas citoquinas, entre las que destaca el IFNα, no existiendo estudios experimentales con productos homeopáticos.

Material y métodos

«In vitro» la línea B16F10 fue tratada durante 24, 48 y 72 horas con IFNα /10 a 1.000.000 UI/ml y con Lymphomyosot 1/1 y 1/3 (v/v), cuantificando la viabilidad celular con el test del MTT. «In vivo» realizamos dos experimentos con 80 ratones machos a los que inyectamos 1×105 células B16F10 y tratamos con: I (PBS), II (IFNα), III (Lymphomyosot) y IV (IFNα más Lymphomyosot), realizando el estudio morfológico.

Resultados

«In vitro» el IFNα a altas concentraciones inhibió el crecimiento celular y el Lymphomyosot no mostró efectos citotóxicos. «In vivo» el IFNα redujo el índice de proliferación celular y la extensión de los infiltrados inflamatorios, mientras que el Lymphomyosot originó disminución significativa de los pesos y necrosis tumorales.

Conclusión

El IFNα ha mostrado citotoxicidad en ambos modelos y el Lymphomyosot ausencia de toxicidad y efecto antitumoral indirecto probablemente al aumentar la respuesta del huésped.

Palabras clave:
C57BL/6J
melanoma B16F10
IFNα
Lymphomyosot
«in vitro»
«in vivo»
Summary
Introduction

Several cytokines are being tested in the treatment of melanoma. Among them IFNα should be highlighted, whilst no other experimental studies using homeopathic products are underway.

Material & Methods

«In vitro»: the cell line B16F10 was treated at 24, 48 and 72 hours with IFNα /10 at 1,000,000 IU/ml and with Lymphomyosot 1/1 and 1/3 (v/v). Cell viability was quantified using MTT test. «In vivo»: two experiments were carried out on 80 male mice which were injected with 1×105 B16F10 cells and treated with: I (PBS), II (IFNα), III (Lymphomyosot) and IV (IFNα plus Lymphomyosot). A morphological study was also performed.

Results

«In vitro»: at high concentrations of IFNα , cell growth was inhibited and Lymphomyosot showed no cytotoxic effects. «In vivo»: IFNα reduced the cell-proliferation rate as well as the extent of spread of inflammatory infiltrates, whilst Lymphomyosot caused a significant tumor weight drop and necrosis.

Conclusion

IFNα displayed cytotoxicity in both models whilst Lymphomyosot had an absence of toxicity and an indirect anti-tumor effect, probably due to an increase in the host's response.

Key words:
C57BL/6J
melanoma B16F10
IFNα
Lymphomyosot
«in vitro»
«in vivo»

Article

These are the options to access the full texts of the publication Revista Española de Patología
Subscriber
Subscriber

If you already have your login data, please click here .

If you have forgotten your password you can you can recover it by clicking here and selecting the option “I have forgotten my password”
Subscribe
Subscribe to

Revista Española de Patología

Purchase
Purchase article

Purchasing article the PDF version will be downloaded

Price 19.34 €

Purchase now
Contact
Phone for subscriptions and reporting of errors
From Monday to Friday from 9 a.m. to 6 p.m. (GMT + 1) except for the months of July and August which will be from 9 a.m. to 3 p.m.
Calls from Spain
932 415 960
Calls from outside Spain
+34 932 415 960
E-mail
Article options
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos